ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS
- Assess disease free survival in patients with idiopathic myelofibrosis treated with a
preparative busulfan/cyclophosphamide regimen followed by allogeneic bone marrow or
peripheral blood stem cell transplantation.
- Determine the risk of primary graft failure in these patients.
OUTLINE: Patients receive a preparative regimen consisting of oral busulfan every 6 hours on
days -7 through -4 and cyclophosphamide on days -3 and -2. Patients then receive allogeneic
bone marrow or peripheral blood stem cells on day 0. Patients registered on protocol
FHCRC-1106.00 randomized to stem cell transplant receive unmodified G-CSF-mobilized stem
cells from an HLA-identical donor.
Patients receive cyclosporine/methotrexate or tacrolimus/methotrexate as prophylaxis for
graft-versus-host disease (GVHD). Patients receiving marrow from unrelated donors are
eligible for appropriate GVHD prophylaxis studies.
Patients are followed at 6 and 12 months after transplant.
PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study over
approximately 3.5 years.
Primary Purpose: Treatment
H. Joachim Deeg, MD
Fred Hutchinson Cancer Research Center
United States: Federal Government
|Fred Hutchinson Cancer Research Center||Seattle, Washington 98109|